The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Open accessAbstract
Introduction: Cerebrospinal fluid analysis and other measurements of amyloidosis, such as amyloid‐binding positron emission tomography studies, are limited by cost and availability. There is a need for a more practical amyloid β (Aβ) biomarker for central nervous system amyloid deposition. Methods: We adapted our previously reported stable isotope labeling kinetics protocol to analyze the turnover kinetics and concentrations of Aβ38, Aβ40, and Aβ42 in human plasma. Results: Aβ isoforms have a half‐life of approximately 3 hours in plasma. Aβ38 demonstrated faster turnover kinetics compared with Aβ40 and Aβ42. Faster fractional turnover of Aβ42 relative to Aβ40 and lower Aβ42 and Aβ42/Aβ40 concentrations in amyloid‐positive participants were observed. Discussion: Blood plasma Aβ42 shows similar amyloid‐associated alterations as we have previously reported in cerebrospinal fluid, suggesting a blood‐brain transportation mechanism of Aβ. The stability and sensitivity of plasma Aβ measurements suggest this may be a useful screening test for central nervous system amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“an 8-year follow-up study of 599 volunteers (average age 70 years) in Australia found that cognitively normal PET amyloid-positive people had an elevated risk of developing Alzheimer's disease compared with amyloid negative (17·7% vs 8·1%; OR 2·4, 95% CI 1·5–4·0).184”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma Aβ measures now show promise [202,203].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [202]
The cited source says what the claim attributes to it.
In the citing paper
“While imaging/CSF biomarker data on subsets of individuals from well-designed community-based cohorts would provide additional research value, incorporating biomarkers on a large scale in many settings will require low-cost and minimally invasive biomarkers (e.g., blood or saliva) that are now emerging [202–205].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [202]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Over 80% of the 266 people who were PET amyloid-positive did not go onto develop a cognitive impairment within 8 years, showing positive status does not predict impairment for most people in a timeframe that might be a useful prognostic window.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Follow-up at 5 years of amyloid-positive participants with normal cognition or mild cognitive impairment versus amyloid negative people found the same pattern of increased risk (2·6, 1·4–4·9).”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Risk also increases per 1 year of age (HR 1·05, 95% CI 0·55–2·0/year), and APOEε4 status (2·6, 1·4–5·0).184”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measuredIn the citing paper
“Blood biomarkers for the presymptomatic phase of Alzheimer’s disease are largely lacking, although recent progress in the analysis of amyloid-β, tau, and neurofilament light chain (NfL) in the blood have been reported5–10.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [8]
In the citing paper
“Recent studies demonstrate the ability to detect CNS Aβ deposition via the use of plasma assessment of Aβ species”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Ovod et al., 2017
In the citing paper
“Most recently, 2 independent groups demonstrated improved accuracy for plasma Aβ42/Aβ40 using immunoprecipitation–mass spectrometry assays.19,20”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [20]
In the citing paper
“In mass spectrometry–based techniques, 2 recent studies have provided overall better accuracies for plasma Aβ42/Aβ40 (AUC, 0.84-0.97 depending on population and reference standard).19,20”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“3%, respectively, when confirmed by postmortem histopathology [4].”
BackgroundLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Self-citationAge but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M. K., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 258
Cited by
Sorted by citations
Items 301–400 of 586
Coulton, J. B., He, Y., Barthélemy, N. R., Jiang, H., Holtzman, D. M., & Bateman, R. J. (2024) · Brain Communications · doi:10.1093/braincomms/fcae247 · Cited by 17
Self-citation“Advances in biomarker discovery and diagnostics for alzheimer’s disease”
Bhatia, V., Chandel, A., Minhas, Y., & Kushawaha, S. K. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08023-y · Cited by 20
Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood
Lee, H., Ugay, D. A., Hong, S., & Kim, Y. S. (2020) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2020.19.1.1 · Cited by 17
Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?
Gong, X., Zhang, H., Liu, X., Liu, Y., Liu, J., Fapohunda, F. O., Lü, P., Wang, K., & Tang, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977999 · Cited by 17
Manjavong, M., Kang, J. M., Díaz, A. S., Ashford, M. T., Eichenbaum, J., Aaronson, A., Miller, M. J., Mackin, S., Tank, R., Weiner, M. W., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.110 · Cited by 16
Ankeny, S. E., Bacci, J. R., Decourt, B., Sabbagh, M. N., & Mielke, M. M. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00658-x · Cited by 22
Mass spectrometric studies of the variety of beta‐amyloid proteoforms in Alzheimer's disease
Zakharova, N. V., Kononikhin, A. S., Indeykina, M. I., Bugrova, A. E., Strelnikova, P. A., Игоревич, П. С., Kozin, S. A., Popov, I. A., Mitkevich, V. A., Makarov, A. А., et al. (2022) · Mass Spectrometry Reviews · doi:10.1002/mas.21775 · Cited by 16
The pathway to secondary prevention of Alzheimer's disease
McDade, E., Bednar, M. M., Brashear, H. R., Miller, D. S., Maruff, P., Randolph, C., Ismail, Z., Carrillo, M. C., Weber, C. J., Bain, L. J., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12069 · Cited by 20
Towards pharmacological prevention of Alzheimer disease
Llibre‐Guerra, J. J., McDade, E., Schindler, S. E., Clifford, D. B., Supnet, C. B., Atri, A., & Bateman, R. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01154-y · Cited by 18
Self-citationHealth Economic Considerations in the Deployment of an Alzheimer's Prevention Therapy
Mattke, S., Jun, H., Hanson, M., Chu, S., Kordower, J. H., & Reiman, E. M. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.23 · Cited by 15
Morgado, B., Klafki, H., Bauer, C., Waniek, K., Esselmann, H., Wirths, O., Hansen, N., Lachmann, I., Osterloh, D., Schuchhardt, J., et al. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01751-2 · Cited by 16
Vanderstichele, H., Teunissen, C. E., & Vanmechelen, E. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00166-3 · Cited by 16
Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer’s Disease
Brod, S. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215125 · Cited by 16
Vu, K. H. P., Lee, M., Blankenburg, G. H., Chang, Y., Chu, M.-L., Erbe, A., Lesser‐Rojas, L., Chen, Y., & Chou, C. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c01521 · Cited by 15
Detection and quantification of Aβ−3–40 (APP669‐711) in cerebrospinal fluid
Klafki, H., Wirths, O., Mollenhauer, B., Liepold, T., Rieper, P., Esselmann, H., Vogelgsang, J. S., Wiltfang, J., & Jahn, O. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15571 · Cited by 15
Gregory, S., Saunders, S., & Ritchie, C. W. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00219-7 · Cited by 16
Martí‐Juan, G., Sanromà, G., & Piella, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211121 · Cited by 16
Pearce, A. M., Marr, C., Dewar, M., & Gow, A. J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.815439 · Cited by 16
Giudici, K. V., Barreto, P. D. S., Guyonnet, S., Morley, J. E., Nguyen, A. D., Aggarwal, G., Parini, A., Li, Y., Bateman, R. J., Vellas, B. J., et al. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac244 · Cited by 14
Self-citationWeiner, S., Blennow, K., Zetterberg, H., & Gobom, J. (2023) · Expert Review of Proteomics · doi:10.1080/14789450.2023.2255752 · Cited by 15
Pedrini, S., Chatterjee, P., Nakamura, A., Tegg, M., Hone, E., Rainey‐Smith, S. R., Rowe, C. C., Doré, V., Villemagne, V. L., Ames, D. J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.771214 · Cited by 16
Yuyama, K., Sun, H., Igarashi, Y., Monde, K., Hirase, T., Nakayama, M., & Makino, Y. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01073-w · Cited by 13
Cullen, N. C., Janelidze, S., Stomrud, E., Bateman, R. J., Palmqvist, S., Hansson, O., & Mattsson, N. (2023) · Brain Communications · doi:10.1093/braincomms/fcad015 · Cited by 14
Self-citationDelrieu, J., Vellas, B. J., Guyonnet, S., Cantet, C., Ovod, V., Li, Y., Bollinger, J., Bateman, R. J., Andrieu, S., on behalf of MAPT/DSA group, et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01325-3 · Cited by 13
Self-citationGiuffrè, G. M., Quaranta, D., Vita, M. G., Costantini, E. M., Citro, S., Carrozza, C., Ninno, G. D., Calabresi, P., & Marra, C. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.58 · Cited by 14
Yu, X., Sun, X., Wei, M., Deng, S., Zhang, Q., Guo, T., Shao, K., Zhang, M., Jiang, J., Han, Y., et al. (2024) · Research · doi:10.34133/research.0354 · Cited by 15
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 20
Blood-based diagnostics of Alzheimer’s disease
Penner, G., Lecocq, S., Chopin, A., Vedoya, X., Lista, S., Vergallo, A., Lejeune, F., & Hampel, H. J. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1626719 · Cited by 13
Wang, D., Dai, Y., Wang, X., Pan, Y., Qu, S., Liu, Z., Cao, Y., Zhang, L., Ying, P., Liu, W., et al. (2021) · Microchimica Acta · doi:10.1007/s00604-020-04650-8 · Cited by 12
The Association of Plasma Amyloid-β and Cognitive Decline in Cognitively Unimpaired Population
Wang, J., Gao, L., Liu, J., Dang, L., Wei, S., Hu, N., Gao, Y., Peng, W., Shang, S., Huo, K., et al. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s357994 · Cited by 14
Zhang, M., Chen, H., Huang, W., Guo, T., Ma, G., Han, Y., & Shu, N. (2024) · Human Brain Mapping · doi:10.1002/hbm.26566 · Cited by 11
Diagnosis of Alzheimer's disease: Towards accuracy and accessibility
Mu, Y., Chang, K., Chen, Y.-F., Yan, K., Wang, C.-X., & Hua, Q. (1970) · Journal of Biological Methods · doi:10.14440/jbm.2024.412 · Cited by 13
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 14
A Blood Test for Alzheimer's Disease: Progress, Challenges, and Recommendations
Kiddle, S. J., Voyle, N., & Dobson, R. (2018) · UCL Discovery (University College London) · Cited by 12
Gao, L., Jiang, Y., Wei, S., Shang, S., Li, P., Chen, C., Dang, L., Wang, J., Huo, K., Deng, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180399 · Cited by 12
Amyloid Metabolism and Amyloid-Targeting Blood-Based Biomarkers of Alzheimer’s Disease
Pyun, J., Kang, M. J., Ryoo, N., Suh, J., Youn, Y. C., Park, Y. H., & Kim, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200104 · Cited by 11
Chronic Traumatic Encephalopathy: A Comparison with Alzheimer's Disease and Frontotemporal Dementia
Lesman‐Segev, O. H., Edwards, L., & Rabinovici, G. D. (2020) · Seminars in Neurology · doi:10.1055/s-0040-1715134 · Cited by 13
Saunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 12
Bittner, T. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.89 · Cited by 12
Associations of liver function with plasma biomarkers for Alzheimer’s Disease
Zhang, B., Zhang, C., Wang, Y., Cheng, L., Wang, Y., Qiao, Y., Peng, D., & Initiative, A. D. N. (2024) · Neurological Sciences · doi:10.1007/s10072-023-07284-9 · Cited by 12
Chen, Y., Zeng, X., Olvera‐Rojas, M., Sewell, K. R., Sehrawat, A., Gu, J. M., Triviño‐Ibáñez, E. M., Solis‐Urra, P., Gómez-Río, M., Oberlin, L. E., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68372-w · Cited by 13
Neurodegenerative Diseases: The Value of Early Predictive End Points
Hsieh, S. J., Alexopoulou, Z., Mehrotra, N., Struyk, A. F., & Stoch, S. A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2544 · Cited by 11
Alzheimer Disease Biomarkers in Clinical Practice: A Blood-Based Diagnostic Revolution
Paczynski, M., & Day, G. S. (2022) · Journal of Primary Care & Community Health · doi:10.1177/21501319221141178 · Cited by 11
Biomedical informatics applications for precision management of neurodegenerative diseases
Miller, J. B., Shan, G., Lombardo, J. M., & Jimenez‐Maggiora, G. A. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.007 · Cited by 11
Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer’s Disease
Bistaffa, E., Tagliavini, F., Matteini, P., & Moda, F. (2020) · Brain Sciences · doi:10.3390/brainsci10110815 · Cited by 11
Hartz, S. M., Mozersky, J. T., Schindler, S. E., Linnenbringer, E. L., Wang, J., Gordon, B. A., Raji, C. A., Moulder, K. L., West, T., Benzinger, T. L. S., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12781 · Cited by 10
Self-citationCatania, M., Battipaglia, C., Perego, A., Salvi, E., Maderna, E., Cazzaniga, F. A., Rossini, P. M., Marra, C., Vanacore, N., Redolfi, A., et al. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00620-5 · Cited by 10
Blood-based biomarkers in mild behavioral impairment: an updated overview
Angelopoulou, E., Androni, X., Villa, C., Hatzimanolis, A., Scarmeas, N., & Papageorgiou, S. G. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1534193 · Cited by 12
Miles, L. A., & Masters, C. L. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251361049 · Cited by 11
Targeted protein quantitation in human body fluids by mass spectrometry
Chen, Y., Liao, W.-R., Wang, H., Chen, H., & Chen, S. (2022) · Mass Spectrometry Reviews · doi:10.1002/mas.21788 · Cited by 10
Rossi, E., Tran, N. T., Hirtz, C., Lehmann, S., & Taverna, M. (2020) · Talanta · doi:10.1016/j.talanta.2020.121002 · Cited by 11
Connecting Mind-Body Therapy-Mediated Effects to Pathological Features of Alzheimer’s Disease
Hüttenrauch, M., López‐Noguerola, J. S., & Castro‐Obregón, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200743 · Cited by 10
Li, M., Li, Y., Schindler, S. E., Yen, D. P., Sutcliffe, S., Babulal, G. M., Benzinger, T. L. S., Lenze, E. J., & Bateman, R. J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13125 · Cited by 9
Self-citationSchraen‐Maschke, S., Duhamel, A., Vidal, J., Ramdane, N., Vaudran, L., Dussart, C., Buée, L., Sablonnière, B., Delaby, C., Allinquant, B., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106459 · Cited by 9
Suárez‐Calvet, M., Ruiz, C. A., Alcolea, D. A., Mendióroz, M., Balasa, M., Morenas‐Rodríguez, E., Puig‐Pijoan, A., Sánchez‐Juan, P., Villarejo‐Galende, A., & Sánchez‐Valle, R. (2024) · Neurología · doi:10.1016/j.nrl.2024.08.002 · Cited by 9
CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer’s disease
Qiang, Q., Skudder‐Hill, L., Toyota, T., Huang, Z., Wei, W., Adachi, H., & Initiative, A. D. N. (2023) · Brain Communications · doi:10.1093/braincomms/fcad312 · Cited by 9
Qiang, Q., Skudder‐Hill, L., Toyota, T., Huang, Z., Wei, W., & Adachi, H. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.122861 · Cited by 10
Liang, R., Ou, S., Han, Y., Xu, J., & Zhou, S. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110737 · Cited by 9
Li, D., Mielke, M. M., Bell, W. R., Reilly, C., Zhang, L., Lin, F. V., & Yu, F. (2020) · Trials · doi:10.1186/s13063-019-3798-1 · Cited by 10
Argentati, C., Tortorella, I., Bazzucchi, M., Emiliani, C., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030115 · Cited by 10
Gao, L., Wang, J., Jiang, Y., Wei, S., Shang, S., Chen, C., Dang, L., Huo, K., Deng, M., Wang, J., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191320 · Cited by 9
Ni, W., Jagust, W. J., & Wang, D. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00424 · Cited by 9
Wei, S., Shang, S., Dang, L., Gao, F., Gao, Y., Gao, L., Chen, C., Huo, K., Wang, J., Wang, J., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210405 · Cited by 8
Faldu, K. G., & Shah, J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2104639 · Cited by 10
Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm
Montoliu‐Gaya, L., & Villegas, S. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2017.12.006 · Cited by 9
Biofluid biomarkers for Alzheimer’s disease
Wang, S., Xie, S., Zheng, Q., Zhang, Z., Wang, T., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380237 · Cited by 9
Sun, W., Ye, S., Wang, Y., Chen, H., Che, P., Chen, J., & Zhang, N. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf094 · Cited by 8
Chronic stress, social support, and Alzheimer's blood‐based biomarkers in the HABS‐HD study
Lee, J. K., Johnson, L. A., Hall, J. R., Bateman, J. R., Barnes, L. L., O’Bryant, S. E., & Mielke, M. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70043 · Cited by 10
Souza‐Talarico, J. N., Perkhounkova, Y., Hein, M., Lee, J., Hefti, M. M., & Sindi, S. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70140 · Cited by 9
Xu, H., Zhang, Y., Shen, L., Yu, S., Li, C., Zeng, X., Liu, Q., & Ye, B. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c02003 · Cited by 8
Suárez‐Calvet, M., Ruiz, C. A., Alcolea, D. A., Mendióroz, M., Balasa, M., Morenas‐Rodríguez, E., Puig‐Pijoan, A., Sánchez‐Juan, P., Villarejo‐Galende, A., & Sánchez‐Valle, R. (2025) · Neurología (English Edition) · doi:10.1016/j.nrleng.2025.07.004 · Cited by 8
Collij, L. E., Mattsson, N., Janelidze, S., Ossenkoppele, R., & Hansson, O. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70763 · Cited by 8
Integrative Multiomics Insights into the Genetic and Epigenetic Architecture of Alzheimer’s Disease
Mishra, A. K., & Jain, S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00750 · Cited by 10
Roh, H. W., Chang, Y. Y., Kim, K. Y., Jeon, S. Y., Wang, S., Kim, E., Bae, J. N., & Ryu, S. (2026) · Psychiatry Investigation · doi:10.30773/pi.2025.0400 · Cited by 8
Proteomic Markers and Early Prediction of Alzheimer’s Disease
Zakharova, N. V., Bugrova, A. E., Indeykina, M. I., Fedorova, Y. B., Колыхалов, И. В., Si, G., Николаев, Е. Н., & Kononikhin, A. S. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922080089 · Cited by 7
Wei, S., Dang, L., Gao, F., Wang, J., Wang, J., & Qu, Q. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220240 · Cited by 8
Dang, L., Wei, S., Zhao, Y. C., Zhou, R., Shang, S., Gao, F., Wang, J., Wang, J., & Qu, Q. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02398-1 · Cited by 8
Biomarcadores en la enfermedad de Alzheimer
Janeiro, M. H., Ardanaz, C. G., Sola-Sevilla, N., Dong, J., Cortés-Erice, M., Solas, M., Puerta, E., & Ramírez, M. J. (2021) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2020-0109 · Cited by 26
Guo, Y., Hu, Z., & Wang, Z. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.778955 · Cited by 8
Achard, V., Ceyzériat, K., Tournier, B. B., Frisoni, G. B., Garibotto, V., & Zilli, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734881 · Cited by 8
Chen, Y., Chen, M., Wang, P., Lu, C., Chen, H.-L., & Lin, W.-C. (2022) · Diagnostics · doi:10.3390/diagnostics12071522 · Cited by 8
Zhang, Q., Bai, K., Jin, X., Zhan, M., Han, L., Zhuang, J., & Huang, X. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116396 · Cited by 7
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization
Osse, A. M. L., Kinney, J. W., & Cummings, J. L. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70050 · Cited by 7
de Rino, F., Rispoli, F., Zuffi, M., Matteucci, E., Gavazzi, A., Salvatici, M., Sansico, D. F., Pollaroli, G., & Drago, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094308 · Cited by 7
Giudici, K. V., Barreto, P. D. S., Guyonnet, S., Cantet, C., Zetterberg, H., Boschat, C., Hudry, J., Andrieu, S., Schmitt, J. A. J., Vellas, B. J., et al. (2023) · Journal of Aging Research and Lifestyle · doi:10.14283/jarlife.2023.7 · Cited by 7
Recent Advances in Photoelectrochemical Sensing of Alzheimer’s Biomarkers
Kim, K. (2023) · BioChip Journal · doi:10.1007/s13206-023-00105-3 · Cited by 8
Wu, K.-Y., Hsiao, I., Chen, C., Liu, C.-Y., Hsu, J., Huang, S., Yen, T., & Lin, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-21140-3 · Cited by 7
Peripheral Markers of Neurovascular Unit Integrity and Amyloid-β in the Brains of Menopausal Women
Jayachandran, M., Miller, V., Lahr, B., Bailey, K., Lowe, V., Fields, J., Mielke, M., & Kantarci, K. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201410 · Cited by 6
Blood‐based biomarkers for Alzheimer's disease
Chohan, P., Dashwood, M., Theodoulou, G., Reed, H., & Kuruvilla, T. (2022) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.764 · Cited by 7
Sekimori, T., Fukunaga, K., Finkelstein, D. I., & Kawahata, K. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2310188 · Cited by 7
Beyond Alzheimer’s disease—translating biomarker insights across CNS diseases
Brady, L. S., Mahinrad, S., Edelmayer, R. M., Potter, W. Z., Hutten, S. J., Anticevic, A., Taylor‐Burds, C., Winston, C. N., Coetzee, T., Paulsen, J. S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr2511 · Cited by 6
Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Bacci, J. R., Karagianni, S., Alexopoulou, Z.-S., Moukaled, S., Tato-Fernández, C., Arunachalam, P., Aslanyan, A., Aye, S., Rocha, A. S. L., Crugel, M., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01921-5 · Cited by 8
Chen, Y., Su, Y., Su, Y., Chen, K., Atri, A., Caselli, R. J., Reiman, E. M., Wang, Y., & Initiative, T. A. D. N. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231162 · Cited by 6
Clinical significance of plasma candidate biomarkers of Alzheimer’s Disease
Lewczuk, P., Łukaszewicz‐Zając, M., Kornhuber, J., & Mroczko, B. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.100675 · Cited by 7
Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
Taylor, R. P., Lindorfer, M. A., & Atkinson, J. P. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12067 · Cited by 5
Nakamura, T., Kawarabayashi, T., Ueda, T., Shimomura, S., Hoshino, M., Itoh, K., Ihara, K., Nakaji, S., Takatama, M., Ikeda, Y., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220996 · Cited by 8
Khalifa, J., Bourgault, S., & Gaudreault, R. (2023) · Current Alzheimer Research · doi:10.2174/0115672050277001231213073043 · Cited by 6
Wei, S., Gao, L., Jiang, Y., Shang, S., Chen, C., Dang, L., Zhao, B., Zhang, J., Wang, J., Huo, K., et al. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.06.011 · Cited by 6
Zhang, W., Liu, Y., Bao, H., Zhang, M., Gao, F., Kang, D., & Shen, Y. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200095 · Cited by 6
Peripheral Blood BRCA1 Methylation Positively Correlates with Major Alzheimer's Disease Risk Factors
Mano, T., Sato, K., Ikeuchi, T., Toda, T., Iwatsubo, T., & Iwata, A. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.31 · Cited by 6
Metadata
- Authors
- Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., Benzinger, T., Fagan, A. M., Patterson, B. W., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-07-19
- Volume
- 13
- Issue
- 8
- Pages
- 841-849
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC5567785
- OpenAlex
- W2736518852
- Cited by
- 585
- References
- 18
- Citations by year
- 2026: 44 · 2025: 44 · 2024: 74 · 2023: 65 · 2022: 84 · 2021: 85 · 2020: 70 · 2019: 66 · 2018: 47 · 2017: 2
- FWCI
- 37.40
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- MetLife Foundation
- AbbVie
- Amgen
- AstraZeneca
- Biogen
- Eisai
- Pfizer
- Sanofi
- Avid Radiopharmaceuticals
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, plasma amyloid-beta
- MeSH terms
- Aged, Amyloidosis, Chromatography, Liquid, Humans, Isotope Labeling, Kinetics, Peptide Fragments, Prospective Studies, ROC Curve, Mass Spectrometry, Biomarkers, Single-Blind Method, Amyloid beta-Peptides, Area Under Curve, Immunoprecipitation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
